Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer.

ABSTRACT:

Purpose

Local failure rates after radiation therapy (RT) for locally advanced non-small-cell lung cancer (NSCLC) remain high. Consequently, RT dose intensification strategies continue to be explored, including hypofractionation, which allows for RT acceleration that could potentially improve outcomes. The maximum-tolerated dose (MTD) with dose-escalated hypofractionation has not been adequately defined.

Patients and methods

Seventy-nine patients with NSCLC were enrolled on a prospective single-institution phase I trial of dose-escalated hypofractionated RT without concurrent chemotherapy. Escalation of dose per fraction was performed according to patients' stratified risk for radiation pneumonitis with total RT doses ranging from 57 to 85.5 Gy in 25 daily fractions over 5 we

SUBMITTER: Cannon DM 

PROVIDER: S-EPMC3837093 | biostudies-literature | 2013 Dec

REPOSITORIES: biostudies-literature